RE: Hacking Pancreatic Cancer: Present and Future of Personalized Medicine23 Jul 2021 00:48
Dr Reader said this back in OCT (bare in mind this was before any gov grants issued).......
The landmark follows similar patent protection being granted to the company in Europe, Japan and China.
Sareum’s CSO Dr John Reader said: “The granting of this patent in the US will complete the protection of the intellectual property for our proprietary SDC-1802 Programme across all major markets.
“The board believes that the patent will enhance the value of its TYK2/JAK1 inhibitor programmes and the company’s negotiating position as it continues to engage in The landmark follows similar patent protection being granted to the company in Europe, Japan and China.
Sareum’s CSO Dr John Reader said: “The granting of this patent in the US will complete the protection of the intellectual property for our proprietary SDC-1802 Programme across all major markets.
“The board believes that the patent will enhance the value of its TYK2/JAK1 inhibitor programmes and the company’s negotiating position as it continues to engage in discussions with potential licence partners.” discussions with potential licence partners.”
I bet the goal post have been moved or would they still be looking at license partners, hmmmmm the silence is deafening. Tick tock tick tock.